{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:10:55Z","timestamp":1774469455799,"version":"3.50.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Infectious Diseases and Microbiology Departments"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>EUCAST recently advised against temocillin use, except for non-serious urinary tract infections (UTI) caused by Escherichia coli, Klebsiella spp. (except Klebsiella aerogenes) and Proteus mirabilis (EKP) treated with a dose of 2 g q8h. We aimed to analyse our practice in the context of a larger temocillin use in France.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>All \u22653 day temocillin prescriptions from 2016 to 2019 were reviewed, with reference to French recommendations and a susceptibility breakpoint of 8 mg\/L. The primary outcome was early clinical failure (antibiotic switch, relapse or death within 10 days after the completion of antibiotic treatment).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 153 cases were analysed: 123 cases of UTI (80.4%) and 133 cases of monomicrobial infection with Enterobacterales (86.9%). A total of 160 Enterobacterales were isolated, comprising 108 (67.5%) ESBL producers and 30 (20.7%) non-EKP species. The rate of early clinical failure was 9.2% and was significantly lower for UTI compared with non-UTI (4.9% versus 26.7%, P = 0.001) and for sepsis compared with severe sepsis or septic shock (6.2% versus 25%, P = 0.011). It was not different between 2 g q12h and 2 g q8h doses (10% versus 7.4%, P = 0.81) and between EKP and other Enterobacterales (8.7% versus 14.3%, P = 0.41).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>EUCAST recommendations on urinary isolates seem to be too restrictive. Our data support the efficacy of temocillin at a dose of 2 g q12h to treat patients with non-severe complicated UTI caused by MDR Enterobacterales with an MIC of \u22648 mg\/L, whatever the species.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa486","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T20:15:14Z","timestamp":1604952914000},"page":"784-788","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-5695","authenticated-orcid":false,"given":"K\u00e9vin","family":"Alexandre","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Rouen University Hospital, Rouen, France"},{"name":"EA 2656 (GRAM 2.0), IRIB, Normandie Univ, Unirouen, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Leysour de Rohello","sequence":"additional","affiliation":[{"name":"Microbiology Department, Rouen University Hospital, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Dahyot","sequence":"additional","affiliation":[{"name":"EA 2656 (GRAM 2.0), IRIB, Normandie Univ, Unirouen, Rouen, France"},{"name":"Microbiology Department, Rouen University Hospital, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-2614","authenticated-orcid":false,"given":"Manuel","family":"Etienne","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Rouen University Hospital, Rouen, France"},{"name":"EA 2656 (GRAM 2.0), IRIB, Normandie Univ, Unirouen, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Tiret","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Rouen University Hospital, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Gillibert","sequence":"additional","affiliation":[{"name":"Biostatistics Department, Rouen University Hospital, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Pestel-Caron","sequence":"additional","affiliation":[{"name":"EA 2656 (GRAM 2.0), IRIB, Normandie Univ, Unirouen, Rouen, France"},{"name":"Microbiology Department, Rouen University Hospital, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Caron","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Rouen University Hospital, Rouen, France"},{"name":"EA 2656 (GRAM 2.0), IRIB, Normandie Univ, Unirouen, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"2021021208580123300_dkaa486-B1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021021208580123300_dkaa486-B2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.medmal.2018.03.005","article-title":"Practice guidelines for the management of adult community-acquired urinary tract infections","volume":"48","author":"Caron","year":"2018","journal-title":"Med Mal Infect"},{"key":"2021021208580123300_dkaa486-B3","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party","volume":"73 Suppl 3","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021021208580123300_dkaa486-B4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhin.2017.07.018","article-title":"The association between infection control interventions and carbapenem-resistant Enterobacteriaceae incidence in an endemic hospital","volume":"97","author":"Hussein","year":"2017","journal-title":"J Hosp Infect"},{"key":"2021021208580123300_dkaa486-B5","doi-asserted-by":"crossref","first-page":"e00079-17","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-\u03b2-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2021021208580123300_dkaa486-B6","year":"2019"},{"key":"2021021208580123300_dkaa486-B7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40262-017-0584-7","article-title":"Pharmacokinetics and pharmacodynamics of temocillin","volume":"57","author":"Alexandre","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2021021208580123300_dkaa486-B8","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"2021021208580123300_dkaa486-B9","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"66","author":"Balakrishnan","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2021021208580123300_dkaa486-B10","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/infdis\/159.5.1005","article-title":"In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 \u03b2-lactamase","volume":"159","author":"Pangon","year":"1989","journal-title":"J Infect Dis"},{"key":"2021021208580123300_dkaa486-B11","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3389\/fmicb.2018.01422","article-title":"Interplay between membrane permeability and enzymatic barrier leads to antibiotic-dependent resistance in Klebsiella pneumoniae","volume":"9","author":"Nicolas-Chanoine","year":"2018","journal-title":"Front Microbiol"},{"key":"2021021208580123300_dkaa486-B12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021021208580123300_dkaa486-B13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkm467","article-title":"Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection","volume":"61","author":"De Jongh","year":"2008","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/784\/36241105\/dkaa486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/784\/36241105\/dkaa486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:19:49Z","timestamp":1613175589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/3\/784\/6012939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,30]]},"published-print":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa486","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,11,30]]}}}